This intervention disrupts the inflammatory cascade initiated by IL-1 release from damaged lung epithelial cells, thereby mitigating neutrophil and monocyte recruitment and reducing the risk of insulin resistance [7,8]. The gene discussed is IL1B; the disease is Insulin resistance.